CAMBRIDGE, Mass., June 1 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced the appointment of three members to the executive management team. Effective immediately, Chief Scientific Officer Joseph Bolen, Ph.D., Chief Medical Officer Nancy Simonian, M.D., and Senior Vice President of Non-Clinical Development Sciences Peter Smith, Ph.D., will lead the Company’s research and development efforts and join the executive management team.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
“The skill, experience and passion that Joe, Nancy and Pete bring to their jobs are unequaled in the industry. Together, they will continue to drive our efforts of bringing new medicines to patients,” says Deborah Dunsire, M.D., President and CEO of Millennium.
Collectively, Drs. Bolen, Simonian and Smith possess more than 60 years of drug development experience:
-- Joe Bolen (Boston, Mass.) joined Millennium in 1999 to lead the Company’s oncology discovery efforts. In 2002 he was appointed Senior Vice President of Discovery, and named Chief Scientific Officer in 2006. Prior to joining Millennium, Joe held positions with Hoechst Marion Roussel, DNAX Research Institute of Molecular and Cellular Biology, Bristol-Myers Squibb Pharmaceutical Research Institute and the National Institutes of Health. -- Nancy Simonian (Wayland, Mass.) joined Millennium in 2001 to lead the Company’s clinical development efforts, and in 2006 was named Chief Medical Officer. She is responsible for all clinical, regulatory, pharmacovigilance and development project management functions at the Company. Prior to joining Millennium, she held a clinical research position at Biogen. Board-certified in neurology, Nancy was previously an assistant clinical professor of neurology at Massachusetts General Hospital and Harvard Medical School. -- Peter Smith (Norwell, Mass.) joined Millennium in 2001 as Senior Vice President of Preclinical Development and was named Senior Vice President of Non-Clinical Development Sciences in 2006. In this role, he oversees preclinical development for all discovery and development programs. Prior to joining Millennium, Peter held positions at Smithkline, Merck, Pharmacia and Searle/Monsanto.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company’s research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is
developing an exciting pipeline of innovative product candidates. The Company’s website is http://www.millennium.com.
This press release contains “forward-looking statements,” including statements about the Company’s growth. Various important risks may cause the Company’s actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company’s dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company’s products; government and third-party reimbursement rates; the commercial success of VELCADE(R) (bortezomib) for Injection and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.
Editors’ Note: This press release is also available under the Media section of the Company’s website at: http://www.millennium.com.
Contacts:
Jennifer Snyder (media) Kyle Kuvalanka (investors)
(617) 444-1439 (617) 761-4734
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comMillennium Pharmaceuticals, Inc.
CONTACT: Media, Jennifer Snyder, +1-617-444-1439, or Investors, KyleKuvalanka, +1-617-761-4734, both of Millennium Pharmaceuticals, Inc.
Web site: http://www.millennium.com/
Company News On-Call: http://www.prnewswire.com/comp/114562.html/
